TY - JOUR
T1 - Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
AU - Goyal, Gaurav
AU - Rajkumar, S. Vincent
AU - Lacy, Martha Q.
AU - Gertz, Morie A.
AU - Buadi, Francis K.
AU - Dispenzieri, Angela
AU - Hwa, Yi L.
AU - Fonder, Amie L.
AU - Hobbs, Miriam A.
AU - Hayman, Suzanne R.
AU - Zeldenrust, Steven R.
AU - Lust, John A.
AU - Russell, Stephen J.
AU - Leung, Nelson
AU - Kapoor, Prashant
AU - Go, Ronald S.
AU - Gonsalves, Wilson I.
AU - Kourelis, Taxiarchis V.
AU - Warsame, Rahma
AU - Kyle, Robert A.
AU - Kumar, Shaji K.
N1 - Funding Information:
Acknowledgements This publication was made possible by CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). There is a lack of data regarding impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes. Patients with prior diagnosis of MGUS, SMM, or PC from 1973 to 2015 (cases) were identified from our institution’s database and compared to those without a known MG (controls). The primary outcome of interest was overall survival (OS). Multivariate analysis was performed to ascertain factors impacting all-cause mortality. We identified 774 patients with a prior diagnosis of MGUS, SMM or SPC (cases) and a control population (1:2) matched for the year of diagnosis (n = 1548). After a median follow-up of 81 months, the cases showed a longer median OS than the controls (71 months vs. 56 months). The improved OS was limited to those with a known prior diagnosis of SMM (80 months) and SPC (95 months), compared to MGUS (60 months). Multivariable analysis revealed that MM patients with known prior MG had less overall mortality than those without, and this was limited to prior SMM/SPC group (HR 0.68, 95% CI: 0.50–0.93), as compared to the MGUS group (HR 0.83, 95% CI: 0.66–1.05).
AB - Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). There is a lack of data regarding impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes. Patients with prior diagnosis of MGUS, SMM, or PC from 1973 to 2015 (cases) were identified from our institution’s database and compared to those without a known MG (controls). The primary outcome of interest was overall survival (OS). Multivariate analysis was performed to ascertain factors impacting all-cause mortality. We identified 774 patients with a prior diagnosis of MGUS, SMM or SPC (cases) and a control population (1:2) matched for the year of diagnosis (n = 1548). After a median follow-up of 81 months, the cases showed a longer median OS than the controls (71 months vs. 56 months). The improved OS was limited to those with a known prior diagnosis of SMM (80 months) and SPC (95 months), compared to MGUS (60 months). Multivariable analysis revealed that MM patients with known prior MG had less overall mortality than those without, and this was limited to prior SMM/SPC group (HR 0.68, 95% CI: 0.50–0.93), as compared to the MGUS group (HR 0.83, 95% CI: 0.66–1.05).
UR - http://www.scopus.com/inward/record.url?scp=85061938417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061938417&partnerID=8YFLogxK
U2 - 10.1038/s41375-019-0419-7
DO - 10.1038/s41375-019-0419-7
M3 - Article
C2 - 30787429
AN - SCOPUS:85061938417
SN - 0887-6924
VL - 33
SP - 1273
EP - 1277
JO - Leukemia
JF - Leukemia
IS - 5
ER -